Dr Lamar speaks with ecancertv at ASH 2016 about phase I dose escalation of CPI-613, a metabolic inhibitor, in combination with bendamustine.
She summarises the incidence and outlook of refractory T cell non-Hodgkin lymphoma (NHL), and the escalation of a small patient subgroup from 2000mg/m2, limited by toxicity.
The overall response rate was 80%, and Dr Lamar describes these initial results as signs of an important crack in the armour of T cell lymphoma.
ecancer's filming at ASH 2016 has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.